A

Arbutus Biopharma Corp
D

ABUS

3.36000
USD
-0.01
(-0.15%)
مغلق
حجم التداول
20,527
الربح لكل سهم
-0
العائد الربحي
-
P/E
-12
حجم السوق
644,107,615
أصول ذات صلة
A
ABEO
-0.11000
(-1.52%)
7.12500 USD
ALNY
ALNY
6.65
(1.50%)
449.19 USD
A
ARWR
1.730
(9.21%)
20.510 USD
C
CRSP
0.853
(1.45%)
59.683 USD
E
EDIT
0.08000
(2.70%)
3.04000 USD
F
FATE
0.00000
(0.00%)
1.08000 USD
MRNA
MRNA
1.330
(4.98%)
28.020 USD
S
SRPT
1.500
(7.39%)
21.810 USD
V
VIR
0.08000
(1.80%)
4.51500 USD
V
VKTX
-0.230
(-0.57%)
40.030 USD
المزيد
الأخبار المقالات

العنوان: Arbutus Biopharma Corp

القطاع: Healthcare
الصناعة: Biotechnology
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.